As an unfavorable prognostic factor in CRC, the Braf mutation rate was 3.7% and 17.3% in CHS1 and CHS3, respectively, indicating poor prognosis in CHS3 (Figure 2B). The gene discussed is LYST; the disease is colorectal carcinoma.